Market closedNon-fractional
Hookipa Pharma Inc/HOOK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Hookipa Pharma Inc
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.
Ticker
HOOK
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
New York, United States
Employees
165
Website
www.hookipapharma.com
HOOK Metrics
BasicAdvanced
$56M
Market cap
-
P/E ratio
-$0.45
EPS
0.92
Beta
-
Dividend rate
Price and volume
Market cap
$56M
Beta
0.92
Financial strength
Current ratio
4.497
Quick ratio
4.186
Long term debt to equity
3.209
Total debt to equity
5.819
Interest coverage (TTM)
-253.28%
Management effectiveness
Return on assets (TTM)
-20.19%
Return on equity (TTM)
-50.55%
Valuation
Price to revenue (TTM)
1.138
Price to book
0.53
Price to tangible book (TTM)
0.53
Price to free cash flow (TTM)
-0.735
Growth
Revenue change (TTM)
235.12%
Earnings per share change (TTM)
-51.46%
3-year revenue growth
36.21%
3-year earnings per share growth
-37.26%
What the Analysts think about HOOK
Analyst Ratings
Majority rating from 6 analysts.
HOOK Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$37M
393.24%
Net income
$14M
-157.66%
Profit margin
39.17%
-111.69%
HOOK Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.22
-$0.17
-$0.22
$0.11
-
Expected
-$0.21
-$0.21
-$0.19
-$0.10
-$0.12
Surprise
5.35%
-19.05%
13.99%
-207.32%
-
HOOK News
AllArticlesVideos
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
GlobeNewsWire·5 days ago
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
GlobeNewsWire·1 month ago
HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Hookipa Pharma Inc stock?
Hookipa Pharma Inc (HOOK) has a market cap of $56M as of July 06, 2024.
What is the P/E ratio for Hookipa Pharma Inc stock?
The price to earnings (P/E) ratio for Hookipa Pharma Inc (HOOK) stock is 0 as of July 06, 2024.
Does Hookipa Pharma Inc stock pay dividends?
No, Hookipa Pharma Inc (HOOK) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Hookipa Pharma Inc dividend payment date?
Hookipa Pharma Inc (HOOK) stock does not pay dividends to its shareholders.
What is the beta indicator for Hookipa Pharma Inc?
Hookipa Pharma Inc (HOOK) has a beta rating of 0.92. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Hookipa Pharma Inc stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.